A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A chemist from RUDN University has created platinum complex compounds that are superior in activity to cisplatin, the drug for the treatment of tumour diseases. The new compounds turned out to be also less toxic to healthy cells.

Platinum-based anticancer drugs — cisplatin, oxaliplatin, and carboplatin — are used for chemotherapy in about half of cancer cases. They penetrate cells and interact with DNA molecules. The process is fatal for rapidly dividing cancer cells because the drugs prevent the duplication of DNA molecules, which is necessary for successful division. Since cancer cells divide rapidly, they are the first to be affected. Still, platinum derivatives have certain disadvantages: low stability under physiological conditions and high toxicity.

To create new drugs, a strategy that involves the development of hybrid molecules is often used in modern chemistry. Such substances consist of two or more active fragments that are linked by a linker into one molecule. They usually have a double action, characteristic of each of the fragments.

A chemist from RUDN University, candidate of biological sciences Kirill Kirsanov, created a series of new drugs: hybrids of cisplatin, lonidamine, and bexarotene. Lonidamine itself has an anti-tumour effect due to its ability to suppress energy metabolism in cancer cells. In combination with radiation therapy, it is used to treat brain tumours. Bexarotene is used for the treatment of lung cancer and breast cancer, as it inhibits the growth of tumour cells of hematopoietic and squamous origin.

A derivative of cisplatin with bexarotene turned out to be the most promising. A combination of succinic acid and ethylenediamine was used as a linker. In tests conducted on four tumour cell lines, the hybrid drug was 80 times more active than bexaroten and 20 times higher on average than cisplatin, and the new drug was 80 times more active than cisplatin on MCF7D cell line. Based on the resulting leading compound, new and more effective anti-tumour medications can be developed.

The paper was published in the journal Inorganica Chimica Acta.

News
All news
Science
27 Jun
RUDN Mathematicians: 5G will cope with traffic when using WiGig

RUDN mathematicians investigated the possibility of combining 5 GNR technology and WiGig — a high-frequency range that allows you to transfer data at speeds up to 10 Gbps. This will smooth traffic fluctuations in 5Gnetworks and cope with user requests.

Science
23 Jun
Scientists Reveal the Water Column of the Yamal Lakes Can Be a Microbial Filter

Scientists from the Winogradsky Institute of Microbiology RAS, RUDN University, St. Petersburg State University and the Tyumen Scientific Centre SB RAS studied the microbial communities from several lakes of the Yamal Peninsula. It turned out that methanotrophs (bacteria that use methane as a source of energy) consume methane more actively in the deep mature lakes of the peninsula than in small thermokarst lakes. In this regard, methane emissions into the atmosphere from the surface of deep lakes are low, and only small (relatively younger thermokarst lakes with constitutional ground ice) can make a significant contribution to methane emissions in the north of Western Siberia. Thus, bacteria perform an important function for the climate balance — they reduce the emission of methane into the atmosphere.

Science
20 Jun
RUDN University Physicists Determine the Optimal Conditions for Holding High-Energy Plasma Clouds in Pyrotron

RUDN University physicists have described the conditions for the most efficient operation of long mirror-based variant of cyclotron in the autoresonance mode. These data will bring better understanding of plasma processes in magnetic traps.